Brand and Other Names:Diabinese
- Classes: Antidiabetics, Sulfonylureas
Dosing & Uses
Dosage Forms & Strengths
Dosage should be individualized based upon patient's response
Type 2 Diabetes
Administer 30 minutes before meal to improve absorption
Middle-aged stable diabetic
- 250 mg/day PO initially; may increase or decrease PRN by 50-125 mg/day at 3- to 5-day intervals
- 100-125 mg/day PO initially; may increase or decrease PRN by 50-125 mg/day at 3- to 5-day intervals
- 100-250 mg/day; a higher dose of 500 mg/day may be required in severe diabetes; should avoid doses >750 mg/day
CrCl <50 mL/minute: Avoid use
CrCl >50 mL/minute: Monitor therapy closely; initial and maintenance dosing should be conservative to avoid hypoglycemia
Use lower initial and maintenance dose in liver impairment; chlorpropamide undergoes extensive hepatic metabolism
Other Indications & Uses
Off-label: Neurogenic diabetes insipidus
Safety and efficacy not established
Not drug of choice in elderly; increased risk of hypoglycemia and drug interactions because of long half-life
Type 2 Diabetes
100-125 mg PO qDay initially; may increase or decrease PRN by 50-125 mg/day at 3-5 day intervals
Serious - Use Alternative
Significant - Monitor Closely
Frequency Not Defined
Associated with greater number of side effects in the geriatric and renally impaired; should not be used as first line agent in these populations
Cholestatic jaundice and hepatitis may occur rarely which may progress to liver failure
Type I diabetes
Hypersensitivity, sulfa allergy
Severe renal impairment
Half life prolonged in renal failure
Efficacy may decrease with prolonged use
Patients with risk of severe hypoglycemia, especiall elderly, debilitated, or malnourished patients, patients with risk factors for cardiovascular events, severe liver impairment
Pregnancy & Lactation
Pregnancy Category: C
Lactation: Excretion in milk unknown/not recommended
A:Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.
B:May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.
C:Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.
D:Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.
X:Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.
NA:Information not available.
Mechanism of Action
Initial effect to increase beta-cell insulin secretion; may also decrease rate of hepatic glucose production, increases insulin receptor sensitivity, and increases number of insulin receptors
Half-Life: 25-48 hr
Duration: 24 hr
Initial effect: Diabetes mellitus: 1 hr; Diabetes insipidus: 1 d
Maximum effect: Diabetes mellitus: 3-6 hr; Diabetes insipidus: 4-5 d
Protein Bound: 60-90%
Vd: 0.13-0.23 L/kg
Metabolism: Moderately to extensively metabolized in the liver
Metabolites: Hydroxychlorpropamide, chlorobenzene-sulfonylurea (inactive)
Excretion: Mainly in urine (80-90%)
Dialyzable: PD: no, HD: no
To view formulary information first create a list of plans. Your list will be saved and can be edited at any time.
Adding plans allows you to:
- View the formulary and any restrictions for each plan.
- Manage and view all your plans together – even plans in different states.
- Compare formulary status to other drugs in the same class.
- Access your plan list on any device – mobile or desktop.
The above information is provided for general informational and educational purposes only. Individual plans may vary and formulary information changes. Contact the applicable plan provider for the most current information.
|1||This drug is available at the lowest co-pay. Most commonly, these are generic drugs.|
|2||This drug is available at a middle level co-pay. Most commonly, these are "preferred" (on formulary) brand drugs.|
|3||This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs.|
|4||This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.|
|5||This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.|
|6||This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.|
|NC||NOT COVERED – Drugs that are not covered by the plan.|
Drugs that require prior authorization. This restriction requires that specific clinical criteria be met prior to the approval of the prescription.
Drugs that have quantity limits associated with each prescription. This restriction typically limits the quantity of the drug that will be covered.
Drugs that have step therapy associated with each prescription. This restriction typically requires that certain criteria be met prior to approval for the prescription.
Drugs that have restrictions other than prior authorization, quantity limits, and step therapy associated with each prescription.
Select a box to add or remove a plan.
Select a class to view formulary status for similar drugs